Brian D. Lichty

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

David F. Stojdl, Brian D. Lichty, Benjamin R. tenOever et al. · Cancer Cell · 2003 · 848 citations · Full text

Life Sciences, Immunology, Oncology +14

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

David F. Stojdl, Brian D. Lichty, Shane Knowles et al. · Nature Medicine · 2000 · 816 citations

Life Sciences, Molecular Biology, Oncology +16

Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2

Sam Afkhami, Michael R. D’Agostino, Ali Zhang et al. · Cell · 2022 · 324 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy

Marie‐Claude Bourgeois‐Daigneault, Dominic G. Roy, Amelia S. Aitken et al. · Science Translational Medicine · 2018 · 295 citations

Medicine, Immunology, Oncology +8

Targeting Tumor Vasculature With an Oncolytic Virus

Caroline J. Breitbach, Naomi S. De Silva, Theresa Falls et al. · Molecular Therapy · 2011 · 199 citations · Full text

Medicine, Cancer Biology, Oncology +15